These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3490445)

  • 1. Immunoresistant metastatic tumor variants can re-express their tumor antigen after treatment with DNA methylation-inhibiting agents.
    Altevogt P; von Hoegen P; Schirrmacher V
    Int J Cancer; 1986 Nov; 38(5):707-11. PubMed ID: 3490445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance of metastatic tumor variants to tumor-specific cytotoxic T-lymphocytes not due to defects in expression of restricting major histocompatibility complex molecules in murine cells.
    Altevogt P; Leidig S; Heckl-Oestreicher B
    Cancer Res; 1984 Nov; 44(11):5305-13. PubMed ID: 6333273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenic variation in cancer metastasis: immune escape versus immune control.
    Schirrmacher V; Fogel M; Russmann E; Bosslet K; Altevogt P; Beck L
    Cancer Metastasis Rev; 1982; 1(3):241-74. PubMed ID: 6985248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-frequency generation of new immunoresistant tumor variants during metastasis of a cloned murine tumor line (ESb).
    Bosslet K; Schirrmacher V
    Int J Cancer; 1982 Feb; 29(2):195-202. PubMed ID: 6977502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: migration, survival and tumor-protectivity of cytotoxic donor cells.
    Zangemeister-Wittke U; Schirrmacher V
    Biotherapy; 1991; 3(4):319-29. PubMed ID: 1786195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cells.
    von Hoegen P; Altevogt P; Schirrmacher V
    Cell Immunol; 1987 Oct; 109(2):338-48. PubMed ID: 3117377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. X. Immunoselection of tumor variants differing in tumor antigen expression and metastatic capacity.
    Schirrmacher V; Bosslet K
    Int J Cancer; 1980 Jun; 25(6):781-8. PubMed ID: 14768708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escape of metastasizing clonal tumor cell variants from tumor-specific cytolytic T lymphocytes.
    Bosslet K; Schirrmacher V
    J Exp Med; 1981 Aug; 154(2):557-62. PubMed ID: 6167655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response.
    Von Hoegen P; Weber E; Schirrmacher V
    Eur J Immunol; 1988 Aug; 18(8):1159-66. PubMed ID: 2970967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal analysis of cytolytic T lymphocyte-mediated lysis of target cells with inducible antigen expression: correlation between antigen density and requirement for Lyt-2/3 function.
    Shimonkevitz R; Luescher B; Cerottini JC; MacDonald HR
    J Immunol; 1985 Aug; 135(2):892-9. PubMed ID: 2409156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suggestive evidence that the highly metastatic variant ESb of the T-cell lymphoma Eb is derived from spontaneous fusion with a host macrophage.
    Larizza L; Schirrmacher V; Graf L; Pflüger E; Peres-Martinez M; Stöhr M
    Int J Cancer; 1984 Nov; 34(5):699-707. PubMed ID: 6500746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones.
    Maryanski JL; Boon T
    Eur J Immunol; 1982 May; 12(5):406-12. PubMed ID: 6178608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of protective and cytotoxic immune responses in vivo against metabolically inactivated and untreated cells of a mutagenized tumor line (requirements for tumor immunogenicity).
    Wehrmaker A; Lehmann V; Dröge W
    Cell Immunol; 1986 Sep; 101(2):290-8. PubMed ID: 2428514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The specificity of H-2-restricted cytotoxic T lymphocytes directed to AKR/Gross leukemia virus-induced tumors. I. Isolation of a selectively resistant variant tumor subclone.
    Green WR
    Eur J Immunol; 1983 Nov; 13(11):863-70. PubMed ID: 6196206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state.
    Weinhold KJ; Wheelock EF
    Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenetic studies on the resistance of mice to highly metastatic DBA/2 tumor cell variants. II. Influence of minor histocompatibility antigens on tumor resistance, gamma-interferon induction and cytotoxic response.
    Schirrmacher V; Landolfo S; Zawatzky R; Kirchner H
    Invasion Metastasis; 1981; 1(3):175-94. PubMed ID: 6821364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes.
    Schirrmacher V; Bosslet K; Shantz G; Clauer K; Hübsch D
    Int J Cancer; 1979 Feb; 23(2):245-52. PubMed ID: 83969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of tumour-associated transplantation antigens by syngeneic cytotoxic T lymphocytes after fusion of tumour cell membrane vesicles to recipient cells.
    Altevogt P
    Scand J Immunol; 1984 Sep; 20(3):255-60. PubMed ID: 6387890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.